- Home
- CLRB vs GRI Comparison
CLRB vs GRI Comparison
Compare CLRB & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRB | GRI |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 1.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CLRB | GRI |
|---|---|---|
| Price | $3.34 | $2.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $644.00 |
| AVG Volume (30 Days) | 37.2K | ★ 957.6K |
| Earning Date | 03-12-2026 | 01-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $2.10 |
| 52 Week High | $20.60 | $311.36 |
Technical Indicators
Market Signals| Indicator | CLRB | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 54.15 |
| Support Level | $3.14 | $2.10 |
| Resistance Level | $3.42 | $2.53 |
| Average True Range (ATR) | 0.20 | 0.53 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 40.34 | 5.60 |
Price Performance
Historical ComparisonAbout CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.